Literature DB >> 24485401

The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: a potential therapeutic opportunity for atherosclerotic thrombosis.

Pengfei Jiang1, Dong Xue2, Yingjia Zhang2, Longwu Ye2, Yuan Liu2, Milan Makale3, Santosh Kesari4, Thomas S Edgington2, Cheng Liu5.   

Abstract

OBJECTIVES: The coagulation protease cascade plays the central requisite role in initiation of arterial atherothrombosis. However, the relative participation of the extrinsic as compared to the intrinsic pathway is incompletely resolved. We have investigated in vivo the relative importance of the extrinsic and intrinsic pathways to define which is more essential to atherothrombosis and therefore the preferable prophylactic therapeutic target. We further addressed which type of plaque associated macrophage population is associated with the thrombotic propensity of atherosclerotic plaques.
METHODS: Both photochemical injury and ferric chloride vascular injury models demonstrated arterial thrombosis formation in ApoE deficient mice. We found that direct interference with the extrinsic pathway, but not the intrinsic pathway, markedly diminished the rate of thrombus formation and occlusion of atherosclerotic carotid arteries following experimental challenge. To explore which plaque macrophage subtype may participate in plaque thrombosis in regard to expression tissue factor pathway inhibitor (TFPI), bone marrow derived macrophages of both M and GM phenotypes expressed tissue factor (TF), but the level of TFPI was much greater in M- type macrophages, which exhibited diminished thrombogenic activity, compared to type GM-macrophages. RESULTS AND
CONCLUSIONS: Our works support the hypothesis that the TF-initiated and direct extrinsic pathway provides the more significant contribution to arterial plaque thrombogenesis. Activation of the TF driven extrinsic pathway can be influenced by differing colony-stimulating factor influenced macrophage TFPI-1 expression. These results advance our understanding of atherothrombosis and identify potential therapeutic targets associated with the extrinsic pathway and with macrophages populating arterial atherosclerotic plaques.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apolipoproteins E; Extrinsic pathway; Intrinsic pathway; Thrombosis; Tissue factor TF; Tissue factor pathway inhibitor TFPI

Mesh:

Substances:

Year:  2014        PMID: 24485401     DOI: 10.1016/j.thromres.2014.01.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

Review 1.  Insights into the Functional Role of ADTRP (Androgen-Dependent TFPI-Regulating Protein) in Health and Disease.

Authors:  Cristina Lupu; Maulin M Patel; Florea Lupu
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

2.  Mild hyperlipidemia in mice aggravates platelet responsiveness in thrombus formation and exploration of platelet proteome and lipidome.

Authors:  Johanna P van Geffen; Frauke Swieringa; Kim van Kuijk; Bibian M E Tullemans; Fiorella A Solari; Bing Peng; Kenneth J Clemetson; Richard W Farndale; Ludwig J Dubois; Albert Sickmann; René P Zahedi; Robert Ahrends; Erik A L Biessen; Judith C Sluimer; Johan W M Heemskerk; Marijke J E Kuijpers
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

3.  Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.

Authors:  Manuel Sánchez Cánovas; David Fernández Garay; Laura Ortega Moran; Jaime Rubio Pérez; Carlos Miguel Guirao Rubio; Miriam Lobo de Mena; Berta Obispo Portero; Jesús Brenes Castro; Yolanda Lage; Diego Cacho Lavin; Ana Belen Rupérez Blanco; Ana Manuela Martín Fernández de Soignie; Jonatan Zacarías Benoit Perejón; Laura Jiménez Colomo; Noel Blaya Boluda; Javier Bosque Moreno; Teresa Quintanar Verduguez; Carmen Rosa Garrido; Roberto Martín Huertas; Carme Font I Puig; Andrés Jesús Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2022-06-06       Impact factor: 3.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.